| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.3 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.054 | 0.3 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.052 | 0.3 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |